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A B S T R A C T
Ischemia-reperfusion injury (I/RI), produced by an initial interruption of organ blood flow and its subsequent
restoration, contributes significantly to the pathophysiologies of stroke, myocardial infarction, renal I/RI, in-
testinal I/RI and liver I/RI, which are major causes of disability (including transplant failure) and even mortality.
While the restoration of blood flow is required to restore oxygen and nutrient requirements, reperfusion often
triggers local and systemic inflammatory responses and subsequently elevate the ischemic insult where the
duration of ischemia determines the magnitude of I/RI damage. I/RI increases vascular leakage, changes tran-
scriptional and cell death programs, drives leukocyte entrapment and inflammation and oxidative stress in
tissues. Therapeutic approaches which reduce complications associated with I/RI are desperately needed to
address the clinical and economic burden created by I/RI. Stem cells (SC) represent ubiquitous and uncommitted
cell populations with the ability to self-renew and differentiate into one or more developmental ‘fates’. Like
immune cells, stem cells can home to and penetrate I/R-injured tissues, where they can differentiate into target
tissues and induce trophic paracrine signaling which suppress injury and maintain tissue functions perturbed by
ischemia-reperfusion. This review article summarizes the present use and possible protective mechanisms un-
derlying stem cell protection in diverse forms of ischemia-reperfusion.
Introduction
Ischemia-reperfusion is a state of pathophysiologic stress produced
by an initial obstruction of blood flow to organ followed by subsequent
perfusion at some later time. The magnitude and duration of ischemia
determines the extent of cell dysfunction and/or death. Although re-
perfusion is required to restore oxygen and nutrient requirements of the
tissues, it also results in the exaggeration of local and systemic in-
flammatory responses which often intensify tissue injury; this phe-
nomenon is known as ‘ischemia reperfusion injury or ‘I/RI’ (Eltzschig
and Collard, 2004; Kalogeris et al., 2012, 2016). I/RI is multifaceted
and exhibits progressive increases in vascular leakage, transcriptional
changes and activation of cell death programs, leukocyte entrapment
and inflammation and oxidative stress (Eltzschig and Eckle, 2011). I/RI
can be caused by any situation which can compromise the blood supply
to an organ. Some of these events can include vascular thrombosis,
atherosclerosis, arterial hypotension, organ transplant, aortic cross-
clamping, cardiopulmonary bypass, sleep apnea and sickle cell disease
(Eltzschig and Collard, 2004; Eltzschig and Eckle, 2011; Kerrigan and
Stotland, 1993).
Different organs exhibit different levels of susceptibility to ischemia
with the brain being perhaps the most I/RI sensitive organ; irreversible
brain damage can become evident within 20 minutes of ischemia (Ordy
et al., 1993). This high I/RI sensitivity reflects two major factors: first,
the brain has the highest metabolic requirements of any organ and
consequently high demands for oxygen and nutrition (Silver and
Erecinska, 1998). Secondly, the brain has lower levels of anti-oxidants,
e.g. superoxide dismutase, catalase, glutathione peroxidase (Kalogeris
et al., 2012, 2016) and heme-oxygenase-1 (Damle et al., 2009), com-
pared to the heart, liver, lungs or kidneys. By comparison, the heart is
the second most susceptible organ with irreversible damage occurring
after only 20 minutes (Jennings, 1969) followed by the kidney, where
organ damage can often occur with 30 minutes of ischemia (Porpiglia
et al., 2007). After these, the next major organ influenced by ischemia is
the intestine. However, it is often difficult to determine a “point of no
return” in intestinal I/RI as initial symptoms of intestine I/RI are often
difficult to detect. If intestinal ischemia is detected and treated within
24 hours, the survival rate for mesenteric I/RI is 50%, however, if it is
detected later, the survival rate drops to 30% (Kalogeris et al., 2012,
2016).
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Oxidative stress is an important facet of I/RI, and I/RI-associated
oxidants are produced by several different enzyme systems including
xanthine oxidase, NADPH oxidase (NOX), uncoupled endothelial nitric
oxide synthase (eNOS) and electron ‘leaking’ from the mitochondrial
transport chain (Kalogeris et al., 2012, 2016) (Wu et al., 2018). Oxi-
dative stress mainly reflects the evolution of toxic oxidants including
superoxide anion radical (O2-), hydrogen peroxide (H2O2), hypo-
chlorous acid (HOCl), and hydroxyl anion (OH.) (Eltzschig and Collard,
2004) (Kerrigan and Stotland, 1993). The neutrophil “respiratory burst”
is one of the main sources of I/RI oxidants which mainly reflects the
release of O2-derived from NADPH oxidase (Fantone and Ward, 1982)
(Kerrigan and Stotland, 1993). Xanthine dehydrogenase is a membrane-
associated enzyme which converts hypoxanthine to xanthine and uses
NAD+ as an electron acceptor. However, under ischemic condition it is
converted by proteolysis to xanthine oxidase which uses O2 molecules
as electron acceptors, thereby leading to accumulation of hypox-
anthine. Upon reperfusion, xanthine oxidase reacts converts hypox-
anthine to xanthine forming both superoxide and hydrogen peroxide in
the presence of oxygen and catalase (Lee et al., 2014) (Wu et al., 2018).
These I/RI evolved ROS help to drive cytokine production (Naik and
Dixit, 2011) by activating oxidant sensitive transcription factors like
nuclear factor kappa B (NF-κB) (Asehnoune et al., 2004), induction of
arachidonic acid and leukotriene B4 synthesis, increasing expression of
cell adhesion molecules e.g. P-selectin, intercellular adhesion molecule
(ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) (Lee et al.,
2007) (Carden and Granger, 2000) creating persistently inflammatory
environment (Eltzschig and Collard, 2004; Wu et al., 2018). NOX ex-
pression and activity are increased during ischemia-reperfusion injury
(Miller et al., 2006) (Nakagiri et al., 2007) (Simone et al., 2014)
(Yokota et al., 2011). The induction of hypoxia inhibitory factor-1a
(HIF-1a) by hypoxic conditions activates NOX. Additionally, phospho-
lipase A2, TNF-α, IL-1b and angiotensin II are all released during re-
perfusion and are also known to activate NOX (Dewald and Baggiolini,
1985). NOX produces O2- which is converted to H2O2 (Wu et al., 2018).
The components of NOX (gp90phox) which are mainly involved in ROS
production are present in phagocytic leukocytes and account for 50-
100% of the increase in oxidant production under inflammatory set-
tings, whereas production of oxidants by other forms of NOX present in
non-phagocytic cells (vascular NOX) release less than 10% of the oxi-
dants generated by leukocytes (Kalogeris et al., 2012, 2016). Ad-
ditionally, oxidative stress leads to oxidation of tetrahydrobiopterin
(BH4), an essential co-factor necessary for NOS coupling. Oxidation of
BH4 leads to its reduction and uncoupling of eNOS which instead of NO.
yields O2- (Landmesser et al., 2003) (Kalogeris et al., 2012; Wu et al.,
2018).
Under normal physiologic conditions, mitochondria represent the
largest intracellular source of ROS; the oxidant pool is increased even
more under I/RI stress. Endogenous mitochondrial antioxidant capacity
is also decreased during I/RI which also contributes to oxidative stress
(Dhalla et al., 2000). Oxidative stress degrades and damages several
classes of macromolecules including lipids, proteins & DNA which lead
to changes in multiple cell signaling pathways (Kalogeris et al., 2012).
I/RI can also activate apoptosis, necrosis and autophagy pathways
(Wu et al., 2018). ROS and Ca2+ overload during I/R leads to the
opening of the mitochondrial permeability transition (MPT) pore which
decreases ATP production and depletes ATP, leading to even greater
ROS production, ionic imbalances, swelling and rupture of cells (ne-
crosis) (Rothermel et al., 1997) (Kalogeris et al., 2012). Previously, the
activation and translocation of the apoptotic-inducing proteins Bax,
Bak, Bid, Puma and BNIP3 into mitochondrial membranes have been
studied in ischemic tissues (Metukuri et al., 2009) (Wei et al., 2006). I/
RI in tissues has also been shown stimulate the release of Omi/HtrA2,
caspase activators, and Endonuclease G, which cause nuclear DNA
fragmentation during apoptosis (Kim et al., 2010) (Nielsen et al., 2008).
While autophagy is upregulated during I/RI (Takagi et al., 2007), it
often fails to fully clear dysfunctional mitochondria which evolve
during reperfusion. This appears to reflect the ability of the high
amounts of ROS and Ca2+ overload released in I/RI to overwhelm the
autophagic clearance capacity which triggers opening of MPT, ulti-
mately leading to cell death. Blocking of autophagy elevates tissue in-
jury; conversely pharmalogic induction of autophagy has been shown to
exert a protective influence in I/RI (Cardinal et al., 2009) (Han et al.,
2018). Necrotic cells are potent immunostimulators that trigger Th1
cytokine production and immune cell infiltration. Furthermore, ATP
released from apoptotic cells via pannexin1 channels acts as an at-
tractant for phagocytes triggering additional successive waves of in-
flammation (Elliott et al., 2009) (Chekeni et al., 2010) (Eltzschig and
Eckle, 2011).
Vascular leakage is another event which occurs during I/RI. Solute
exchange is governed by the integrity of cell-cell junctions including
tight and adherens junctions at apical and lateral surfaces and gap
junctions and desmosomes at basal surface. The adherens junctions are
mainly comprised of cadherins like E-, N-and VE-cadherins (in en-
dothelium) and nectins, whereas tight junctions are mainly comprised
of claudins, occludin and junctional adhesion molecules (JAMs e.g.
JAM-A, JAM-C and PECAM-1) (Campbell et al., 2017; Dejana, 2004). I/
R disrupts assembly and barrier properties of both tight and adherens
junctions. There is an I/RI mediated increase in intracellular calcium
levels which activates transcription factors e.g. NF-κB and lead to
changes in tight and adherens junction protein expression, metallo-
proteinase mediated proteolysis and blood-brain barrier disruption
(Davis et al., 2001; Sasaki et al., 2003).
Importantly, our lab has demonstrated that oxidants e.g. H2O2 can
trigger the internalization of VE-cadherin (Kevil et al., 2000) as early as
5 mins following exposure to these mediators with similar transient
changes in cell surface VE-cadherin observed with exposure to hista-
mine, another inflammatory mediator and to EDTA. These events were
seen to depend on actin-filament binding and activation of PKC. The
internalization of junctional elements e.g. VE-cadherin from the cell
surface withdraws these junctional elements from participating in cell-
cell opposition and explains how changes in the spatial organization of
junctional proteins create disturbances in solute permeability in in-
flammation like I/RI.
The release of ROS, chemokines e.g. RANTES and prostanoids e.g.
PAF and LTB4 cause phosphorylation and degradation of endothelial
junctional molecules (Kumar et al., 2009) (Kalogeris et al., 2012).
Previously, it has been shown that claudin-1, ZO-1 and ZO-2 translocate
from the plasma membrane to the cytoplasm under hypoxic conditions
(Bednarczyk and Lukasiuk, 2011). VEGFR-2 dependent phosphoryla-
tion of occludin and loss of ZO-1 has been demonstrated in retinal
ischemia reperfusion (Muthusamy et al., 2014). The significant reduc-
tions in the expression of adherens junction protein, N-cadherin, and
increase in active form of gap junction protein, connexin 43, has been
found in heart I/RI rabbit models (Tansey et al., 2006). The endothelial
actin cytoskeleton is involved in the maintenance of cell-cell adhesion
complexes and cell-matrix adhesion complexes and have been shown to
be disrupted during acute forms of kidney injury. The detachment of
endothelial monolayers from the extracellular matrix has also been
observed during renal ischemia leading to greatly increased perme-
ability of glomerular monolayers and loss of the endothelial barrier
function (Sutton, 2009). Therefore, cell detachment and internalization
of cell-cell junctional molecules represent important processes which
lead to increased vascular permeability and tissue edema in I/RI.
Dead cells and/or damaged contents such as ATP, heat shock pro-
tein, S100 proteins are collectively known as ‘damage associated mo-
lecular patterns’ (DAMPs). Binding of DAMPs to toll-like receptors
(TLRs) expressed on immune cells elicit inflammatory responses and
activate macrophages, dendritic cells, endothelial cells to mobilize the
complement cascade. Increases in cytosolic calcium and ROS genera-
tion during I/RI can also activate macrophages, neutrophils and en-
dothelial cells (de Groot and Rauen, 2007; Kalogeris et al., 2012). ROS
stimulate leukocyte-endothelial adhesion (Alvarez and Sanz, 2001) and
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decrease the bioavailability of NO which normally inhibits leukocyte-
endothelium binding, diminution of NO can intensify inflammation
several-fold (Pierini and Bryan, 2015). NF-κB also regulates the ex-
pression of Bcl-2, TNF-α, ICAM-1, VCAM-1 and E-and P-selectin in-
directly activating inflammation and apoptosis. Normally, NF-κB is in-
active, however, I/RI activates NF-κB and pharmacological inhibition of
NF-κB has been shown to suppress many features of I/RI injury (Matsui
et al., 2005; Wu et al., 2018). TNF-α, upon binding to its receptors also
activates NF-κB and induces expression of adhesion molecules (Son
et al., 2004). ROS also increase intracellular calcium levels leading to
activation of non-specific activation of proteases (metalloproteinases or
‘MMPs’) and phospholipases which drive the synthesis of pro-in-
flammatory prostaglandin mediators such as leukotrienes, thromboxane
as well as platelet activating factor (PAF), and lysophosphatidic acid
(Peplow and Mikhailidis, 1990) (Kerrigan and Stotland, 1993). Leuko-
triene B4 (LTB4) is a potent chemoattractant for leukocytes which in-
creases neutrophil adhesion, transmigration and release of ROS and
proteolytic enzymes from neutrophil granules (Bomalaski et al., 1990)
(Christmas et al., 2006). Similarly, PAF promotes platelet accumula-
tion, aggregation, increases vascular permeability and also increases
leukocyte activation (Stokes and Granger, 2012) (Kubes et al., 1991)
(McDonald, 1994). Activated neutrophils release ROS, additionally
macrophages, endothelial cells and platelets can also release significant
levels of ROS, protease, elastase and cytokines such as TNF-α, IL-8
which all provide chemotactic signals for neutrophils maintaining the
inflammatory milieu, sustaining cytotoxicity and cell injury (de Groot
and Rauen, 2007; Eltzschig and Collard, 2004; Kalogeris et al.,
2012).The disruption of the vascular endothelial barrier after hypoxic
insults also potently triggers neutrophil trafficking which further dis-
rupt tissue integrity and cause extravascular fluid leakage and edema
formation (Eltzschig and Collard, 2004).
Heparin-binding protein (HBP) is one factor released by neutrophils
that causes calcium-dependent cytoskeletal changes in endothelial cells
which cause vascular leakage (Eltzschig and Collard, 2004). Leukocyte-
endothelial aggregation, platelet-leukocyte aggregates and fluid accu-
mulation in tissues leads to the ‘no-reflow’ phenomenon causing con-
tinuous organ dysfunction even after reperfusion (Reffelmann et al.,
2003) (Maxwell and Lip, 1997).
The complement factors C3a, C5a, iC3b and C5b-9, are all known to
be activated during I/RI. The complement cascade can also induce the
expression of VCAM-1, ICAM-1, E-selectin and P-selectin which all
drive leukocyte trafficking and recruitment in I/RI. C5a stimulated
leukocyte activation also induces the release of pro-inflammatory cy-
tokines such as IL-1b, IL-6, MCP-1 and TNF-α (Collard et al., 1999)
(Czermak et al., 1999). C5b-9 can also induce expression of IL-8 and
MCP-1 and can inhibit endothelial-dependent vasodilation (Stahl et al.,
1995) (Kilgore et al., 1997) (Collard et al., 1999). JAK/STAT signaling
pathway transduces signals for various cytokines and growth factors
e.g. IL-2, IL-6, IFN-γ and PDGF and thus plays a role in cell prolifera-
tion, migration and apoptosis. The pharmacological inhibition of the
JAK/STAT pathway has been shown to attenuate experimental renal I/
RI in rats (Yang et al., 2008).
1. Stem cells
Stem cells (SC) are unspecialized cells with the ability to self-renew
and differentiate to one or more developmental ‘fates. SC are critical in
tissue homeostasis and repair (Kolios and Moodley, 2013). Differ-
entiation potential of stem cells varies among stem cells and depends
mainly on their origin (Rossant, 2001b). According to their differ-
entiation potency, all stem cells can be categorized into five different
groups (Fig. 1): 1-Totipotent or omnipotent which can differentiate to
all types of cells in the body (Rossant, 2001a); 2-Pluripotent which can
produce all cell types, excluding cells of the embryonic membrane
(Takahashi and Yamanaka, 2006); 3-Multipotent stem cells are able to
differentiate into many, but not all cell types (Ratajczak et al., 2012); 4-
oligopotent cells can divide and self-renew but without differentiation
(Majo et al., 2008); 5-unipotent stem cells can self-renew and differ-
entiate into a single lineage (Overturf et al., 1997).
Although stem cells are found in many different sources, they share
many common properties, still differ in terms of rates of differentiation,
secretion of trophic factors, as well as the ability to be stimulated by
endogenous signaling mechanisms under pathologic conditions
(Kalladka and Muir, 2014).
1.1. Stem cell classification based on their origin
Stem cells can be classified, based on their origin, into 5 different
groups of embryonic, fetal, perinatal, adult, and iPS (Fig. 1) (Ilic and
Polak, 2011) (Kolios and Moodley, 2013).
1.1.1. Embryonic stem cells (ESCs)
Embryonic stem cells (ESCs) which are derived from the inner cell
mass of pre-implantation embryo, possess the capability of unlimited
self-renewal and expansion (Hao et al., 2014; Madigan and Atoui, 2018;
Nadig, 2009). ESCs are also pluripotent meaning that they have the
ability to differentiate into all cell types of the organism under specific
culturing condition in vitro (Broughton et al., 2012).
Major limitations regarding the use of ESCs include ethical issues,
immune rejection, their fetal age, its malignant transformation to tumor
following transplantation, and limited sources (Hao et al., 2014)
(Broughton et al., 2012).
1.1.2. Fetal stem cells
Fetal stem cells are cell types isolated from fetal tissues and can
differentiate into the various organ systems of the body. There is an
abundant literature suggesting that fetal stem cells have greater plas-
ticity and a higher capacity for replication compared to adult stem cells
(O'Donoghue and Fisk, 2004). Fetal stem cells can be divided into
neural crest stem cells, fetal hematopoietic stem cells, and fetal me-
senchymal stem cells (Beattie et al., 1997).
1.1.2.1. Neural crest stem cells. Neural crest cells are a transient stem
cell-like population that form in the dorsal neural plate border during
neurulation (Liu and Cheung, 2016) (Nyffeler et al., 2017) and then
they migrate to their target sites during development, where they can
differentiate into variety of cell types such as sensory neurons, glia,
melanocytes, adrenal medulla, and cranial cartilage/bones (Nyffeler
et al., 2017) (Villa et al., 2000).
1.1.2.2. Fetal hematopoietic stem cells. Like other stem cells, HSC
collected from fetal blood have the capacity of self-renewal and
proliferation, but at a higher rate (shorter doubling time) compared
to those found in cord blood or adult bone marrow-derived SC
(O'Donoghue and Fisk, 2004). Both adult and fetal HSC are
characterized by the expression of ‘hematopoietic’ CD34 antigen, as
well as absence of CD38 and HLA-DR markers (Madigan and Atoui,
2018; O'Donoghue and Fisk, 2004).
1.1.2.3. Fetal mesenchymal stem cells (fMSCs). fMSCs are multipotent
stromal cells which have higher self-renewal and differentiation
capacity (O'Donoghue and Chan, 2006); (Ljung et al., 2019), longer
telomerase, superior telomerase activity when compared to adult
mesenchymal stem cells (Campagnoli et al., 2001); (Rufaihah et al.,
2018).
1.1.3. Perinatal stem cells
Perinatal (infant) stem cells can be easily obtained at birth from
extra-embryonic structures such as amniotic fluid (AF) (Prasongchean
et al., 2012), umbilical cords (UC) (Majore et al., 2011), and placenta
membranes (Balbi and Bollini, 2017) (Abbaspanah et al., 2018).
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1.1.3.1. Amniotic fluid stem cells. Amniotic fluid contains multiple cell
types, mainly with mesenchymal properties including self-renewal and
differentiation potential (In 't Anker et al., 2003). Amniotic fluid-
derived mesenchymal stem cells can be collected during pregnancy via
amniocentesis or at the end of gestation (Balbi and Bollini, 2017).
1.1.3.2. Umbilical cord stem cells (UCSC). Umbilical cord blood
collected post-natally is the most abundant source of stem cells,
particularly hematopoietic and mesenchymal stem cells (Weiss and
Troyer, 2006). UCSC which are fibroblast-like, spindle-shaped cells
have been easily extracted and expanded in vitro without losing their
immunomodulatory properties (Madigan and Atoui, 2018).
1.1.3.3. Placenta-derived stem cells. The human placenta has been
recognized as a rich source of stem cells based on the expression of
pluripotency markers on hPMSC, and their demonstrated ability to
differentiate into multiple different cell lineages, in addition to their
ability to secrete paracrine factors with anti-inflammatory, anti-
bacterial, anti-fibrotic actions (Azizian et al., 2018) (Beeravolu et al.,
2017) (Bollini et al., 2018). Different stem cell-like populations can be
isolated from different parts of placental tissues including human
amniotic epithelial cells (hAEC), amniotic mesenchymal stromal cells
(hAMSC), chorionic mesenchymal stromal cells (hCMSC), human
umbilical cord mesenchymal stem cells (hUCMSC), and placenta-
derived adherent cells (PDA-001). Placental-derived stem cells express
cell surface markers which have previously identified in bone marrow-
derived stem cells (e.g. CD13, CD29, CD44, CD73, CD90, CD105,
CD166, MHC I) and pluripotent stem cells (e.g. SSEA4, Tra-160, Tra-
181, Oct-4, Nanog, or Sox-2) (Xu et al., 2018) (Maximova et al., 2017)
(Mathew and Bhonde, 2017) (Bollini et al., 2018).
The placenta could be a significant source of therapeutic SC since it
is a very rich source of stem cells which can be readily obtained,
without the need of invasive procedures for isolation and without
ethical complications (Mathew and Bhonde, 2017) (Talwadekar et al.,
2015). The unique immunomodulatory properties of placenta-derived
stem cells in suppression of proliferation, maturation and function of T-
cells, macrophages, and monocyte-derived dendritic cells make them a
suitable source of MSCs (Del Fattore et al., 2015; Shehadah et al.,
2014).
PDACs (placenta-derived adherent cells) are characterized by their
CD34-, CD10+, CD200+, and CD105+ expression. The intramuscular
injection of PDAC stimulates vascular remodeling, attenuates oxidative
stress, and improves limb function. PDAC represent an important
therapeutic tool that requires no histocompatibility tissue matching and
is far more convenient and expeditious to use compared to BM or adi-
pose-derived MSC. PDA-001 is a standardized formulation of PDAC
which is being used intravenously for the treatment of Crohn’s disease
(Wu et al., 2017) (Shehadah et al., 2014).
1.1.4. Adult stem cells (ASCs)
ASCs, also known as tissue resident stem cells, are found in post-
natal individuals, and are either multi- or unipotent (Kolios and
Moodley, 2013). Multipotent ASC can be further categorized as hema-
topoietic stem cells (HSC) (Gilbert et al., 2012), neuronal stem cells
(NSC), and mesenchymal stem cells (MSC) (Dulak et al., 2015) (Liu
et al., 2016). Epidermal stem cells (ESC) are classified as unipotent
adult stem cells which have the ability to differentiate into only one cell
type; e.g. keratinocytes (Dulak et al., 2015).
1.1.4.1. Hematopoietic stem cells (HSCs). HSCs comprise a heterogenous
population of cells that normally resides in the bone marrow (Morrison
and Scadden, 2014). HSCs have the ability to self-renew and
differentiate into the most hematopoietic system lineages such as
myeloid, lymphoid, megakaryocytic, and erythroid (Upadhaya et al.,
2018) (Christensen and Weissman, 2001). HSCs are critical for
maintaining the blood system through hematopoiesis throughout the
lifetime of an organism (Tajer et al., 2019).
1.1.4.2. Neural stem cells (NSCs). Endogenous NSCs: endogenous NSCs,
located in the dentate gyrus of the hippocampus, the sub-ventricular
zone (SVZ), and the olfactory bulb (Zhou et al., 2019) (Lakshman et al.,
2018), act mainly by producing neurotrophic factors such as NGF and
glial cell line-derived neurotrophic factor (GDNF); releasing
proangiogenic complexes (netrin-4, laminin, and integrins); regulating
the inflammatory environment; and secreting factors to promote
synaptic plasticity such as thrombospondins (Stenudd et al., 2015)
(Xu et al., 2019) (Hao et al., 2014).
Exogenous NSCs: Major potential sources of exogenous NSCs could
include ESCs, iPSCs, bone marrow and adipose-derived MSCs, em-
bryonic NSCs, and stem cells from the fetal and adult nervous system.
These cells are able to proliferate in the presence of various growth
factors such as EGF, FGF, and leukemia-inhibiting factor (LIF), and
differentiate into neurons, astrocytes, and oligodendrocytes (Koch
et al., 2009) (Hou et al., 2017) (Hu et al., 2019) (Hao et al., 2014) and
Fig. 1. Classification of stem cells.
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may support and restitute components of the central and peripheral
nervous system.
1.1.4.3. Mesenchymal stem cells (MSCs). MSCs are defined as
multipotent cells with the capacity for self-renewal (da Silva Meirelles
et al., 2008). MSCs have been isolated from almost all mesodermal
layers of mesenchymal tissues including circulating blood (Wang et al.,
2008), adult and fetal bone marrow (BM), spleen, cartilage, muscle
tendons (Salingcarnboriboon et al., 2003), adipose tissues (Zuk et al.,
2001), periosteum (Nakahara et al., 1991), synovial fluid (De Bari et al.,
2001), thymus, trabecular bone, dermis, dental pulp and the lung (Hao
et al., 2014; Ishikawa et al., 2013; Kalladka and Muir, 2014; Merino-
Gonzalez et al., 2016; Sabatini et al., 2005).
The major criteria to define MSCs, based on the ‘Society for Cellular
Therapy’ proposal, include plastic adherence of the isolated cells in
culture, the expression of CD105, CD73, and CD90, and their lack of
expression of CD34, CD45, CD14 or CD11b, CD79a or CD19, and HLA-
DR in more than 95% of the culture, and ultimately, the differentiation
of MSCs into osteoblasts, adipocytes, chondroblasts, neural cells, he-
patocytes, insulin-producing cells, and numerous additional cell types
(Thomson et al., 1998).
A remaining and major concern regarding the source of MSCs has
been how to optimize an isolation procedure in order to obtain enough
cells from a single donor (Del Fattore et al., 2015) which is still a
technical challenge for therapy.
1.1.4.4. Epithelial stem cells. The continual cell replacement of
epithelial tissues during homeostasis is directly supported by
epithelial stem cells which have the capacity for self-renewal and
differentiation (Li et al., 2018b) (Zhou et al., 2016). Epithelial stem
cells mostly reside in intestine and epidermis both of which are typical
epithelial tissues (Boehnke et al., 2012). Epithelial stem cells exhibit
many diverse morphological and functional characteristics; moreover,
they show substantially different homeostatic turnover rate (Fuchs,
2009) (Blanpain et al., 2007). For example, the intestinal epithelium is
completely self-renewed within ~5 days, while interfollicular
epidermis takes ~4 weeks to be replaced (Blanpain et al., 2007).
1.1.4.4.1. Gastrointestinal epithelial stem cells. Gastrointestinal stem
cells are located in a “niche” in the intestinal crypts and gastric glands,
and are responsible for the continuous renewal and regeneration of the
mucosal epithelium both normally and after injury (Rao and Wang,
2010; Kalita et al., 2019; Rao and Wang, 2010).
1.1.4.4.2. Epidermal stem cells. Skin epidermal stem cells which
reside in the basal layer of the inter-follicular epidermis, are capable
of continual self-renewal and differentiation to repair the epidermis and
maintain tissue homeostasis after injury (Veltri et al., 2018) (Jackson
et al., 2017). Epidermal stem cells are considered to be multipotent
adult stem cells that could be beneficial in treatment of different skin
diseases including pemphigus and epidermolysis bullosa (De Rosa et al.,
2014) and stable vitiligo (Falabella et al., 1992).
1.1.4.5. Hepatic stem cells. Longstanding liver injury activates
functional stem cells of the liver which are located within the
intrahepatic biliary tree (Bautista et al., 2019) (Alison et al., 2007).
These so called hepatic stem cells can give rise to cords of bipotential
hepatic progenitor cells, and ultimately differentiate into hepatocytes
and biliary epithelial cells (Liu et al., 2019b). Bone marrow also
contains a population of stem cells with hepatic potential which may
contribute to hepatocyte regeneration when it becomes reprogrammed
for liver recovery (Lagasse et al., 2000).
1.1.5. Induced pluripotent stem cells (iPS)
iPS cells are embryonic stem (ES) cell-like cells that are repro-
grammed from differentiated somatic and germ cells by the induction of
specific transcription factors (Yu et al., 2007); (Awe et al., 2013) (Li
et al., 2018a) (Takahashi and Yamanaka, 2013). iPS cells have the
capacity of unlimited self-renewal and differentiation to create all three
germ lines. The advantage of using iPS cells include the generation of
iPS cells from a patient’s own somatic cells (such as fat cells, nerve cells,
skin fibroblast, B cells, T cells, peripheral blood mononuclear cells)
without ethical issues (Li et al., 2018a). While the risk of rejection of iPS
cells has been shown to be low when administered to the same in-
dividual, it has been reported that the immunogenicity of iPS cells
could change because of fatal errors or mutations during reprogram-
ming and differentiation processes (Li et al., 2018a; Takahashi and
Yamanaka, 2013; Yasuda et al., 2018).
2. Stem cell therapy
Stem cell characteristics make them valuable candidates in a wide
range of biological and medical applications (Chien, 2008). Stem cells
provides the opportunity to investigate and develop more effective and
safer therapies with the capability to replace and regenerate damaged
tissues (Lodi et al., 2011) (Inoue and Yamanaka, 2011).
While stem cells have been studied extensively for their ability to
differentiate into variety of cell types, recent studies have also sug-
gested that acute beneficial effects of stem cells depend instead on their
paracrine signaling actions (Park et al., 2018) (Tachibana et al., 2017)
(Merino-Gonzalez et al., 2016). Paracrine function of stem cells are
related to the secretion of several trophic factors including cytokines,
chemokines, and extracellular matrix protein into the surrounding en-
vironment (Mirotsou et al., 2011) (Hao et al., 2014; Merino-Gonzalez
et al., 2016), which might act as trophic immunomodulators, angio-
genic factors, anti-apoptotic factors, antioxidants molecules and cel-
lular chemotaxis-inducers (Mancuso et al., 2019) (Tsuji et al., 2018)
(Merino-Gonzalez et al., 2016) (Fig. 2). MSCs exert their beneficial ef-
fects by introducing neurotrophic factors such as HGF, VEGF, NGF,
BDNF, bFGF, FGF-2, and IGF-1 into the environment which maintains
survival of many cell types including neurons. It has been reported that
extracellular vesicles and microvesicles (MVs) released from MSCs also
contribute to these ‘paracrine’ forms of signaling (Liu et al., 2019a) (Li
et al., 2019) (Merino-Gonzalez et al., 2016).
In the next section of this review, we discuss potential protective
mechanisms of stem cells in the setting of ischemia-reperfusion injury
of several organs including brain, heart, liver, intestine, kidney, and
eye. Fig. 3 describes the protective effects of stem cells in organ-specific
IR injury.
2.1. Stem cells in ischemic stroke
Stroke remains the main cause of severe disability and mortality in
adults (Rodrigo et al., 2013) (Tong et al., 2019) (Hao et al., 2014). The
incidence and occurrence of stroke has increased with changing de-
mographics of aging in both developed and developing countries.
Thromboembolism accounts for up to 85% of the forms of cerebral
ischemia, while hemorrhage resulting from hypertension or vessel wall
pathology accounts for the remainder (15%) of strokes (Amarenco
et al., 2009) (Adams Jr. et al., 1993) (Mozaffarian et al., 2016)
(Kalladka and Muir, 2014). Ischemic stroke is defined as a sudden oc-
clusion of one or more cerebral arteries due to either thrombosis or
embolus, and provokes an acute loss of neurons, astroglia, oligoden-
droglia and causes disruption of cortical synaptic structure (Sacco et al.,
2013) (Hao et al., 2014; Kim et al., 2018).
Several complex molecular events frequently lead to irreversible
tissue injury following cerebrovascular occlusion, including failure of
energy synthesis, loss of transmembrane ionic gradients, neuronal cell
depolarization and excitotoxicity (Murphy et al., 2008) (Kalladka and
Muir, 2014). Other processes involved in ischemic injury include lo-
calized inflammatory responses with infiltration of neutrophils and
macrophages from the blood into brain tissue and impairment of the
blood brain barrier (Siesjo, 1992) (Chamorro and Hallenbeck, 2006)
(Kalladka and Muir, 2014). Early functional recovery of damaged tissue
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around the infarcted area could reflect the resolution of edema and
inflammation, however, immunomodulation, angiogenesis, endogenous
neurogenesis, and altered gene expression might also be involved in
long term recovery of ischemic brain tissue (Amantea et al., 2009)
(Stanimirovic et al., 1997) (Kalladka and Muir, 2014). Mechanistically,
stem cell therapies have been demonstrated to be effective in en-
dogenous recovery of injured tissue from ischemic stroke, which de-
pends critically upon the timing and method of their administration
(Del Fattore et al., 2015).
Several studies revealed that many types of adult stem cells circulate
in peripheral blood and then become directed to migrate towards sites
of injury, where they contribute to tissue repair (Merino-Gonzalez et al.,
2016). Upon injury, bone marrow-derived stem cells (including hema-
topoietic stem cells (HSCs), mesenchymal stem cells (MSCs), en-
dothelial progenitor cells (EPCs), and very small embryonic like stem
cells (VSELs)) can all be mobilized from the bone marrow and migrate
into the systemic vasculature (Jeong et al., 2003). These cell types can
then penetrate the central nervous system and help to improve neuronal
injury (Ishikawa et al., 2013). This process can be brought about by
activation of cerebral vascular endothelial cell which supports rolling
and adhesive molecules (Ruster et al., 2006) as well as by oxidant
(H2O2) mediated-activation of integrins on stem cell (Kavanagh et al.,
2015) which increases their binding to endothelial adhesive determi-
nants.
Therefore, in response to brain injury, the CNS recruits mobilized
HSC and promotes their migration into tissues both by releasing
neurotransmitters from nerve terminals within bone marrow and
through sympathetic release of neurotransmitters into blood circulation
(Ishikawa et al., 2013). Homing of MSCs begins within the active in-
flammatory zone in the injured tissue from which homing signal ori-
ginated (De Becker and Riet, 2016) (Ishikawa et al., 2013) (Kalladka
and Muir, 2014). The preferential migration of intravenously or in-
tracerebrally injected MSCs to the ischemic sites might be mediated by
factors including SDF-1 (Ruster et al., 2006), IL-8 (Coultas et al., 2005),
MCP-1 (Belema-Bedada et al., 2008), MIP-1a (macrophage in-
flammatory protein-1a) (Wu et al., 1990) (Thored et al., 2006), VEGF
(Walter et al., 2005) or CXCL12 (Levesque et al., 2003) chemokine
receptors (Hao et al., 2014; Ishikawa et al., 2013; Kalladka and Muir,
2014). In the ischemic brain, increased migration of neuroblasts to peri-
infarct regions is mediated by soluble molecules and their receptors,
including angiopoietin-1 (Ang1)/Tie2, stromal derived factor-1a/che-
mokine receptor 4 (CXCR4) (Zhang et al., 2016).
Increased levels of neurotrophic factors such as SDF-1, VEGF-A,
GDNF, BDNF, NGF, IGF, EGF, and bFGF might help provide a basis for
suppression of apoptosis, glutamate excitotoxicity, and oxidative stress
and the increased neuron survival and anti-inflammatory activities seen
with MSCs in the treatment and recovery from ischemic brain injury
(Hao et al., 2014). Systemically (intravenous) administered NSCs effi-
ciently emigrate to injured ischemic area and release neuroprotective
cytokines like VEGF-A (Harms et al., 2010), BDNF (Kurozumi et al.,
2004) (Benraiss et al., 2001), GDNF, FGF-2 (Ikeda et al., 2005), NGF,
and neurotrophins which promote angiogenesis, immunomodulation,
Fig. 2. Paracrine functions of stem cells.
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and endogenous neurogenesis after ischemic stroke (Chen et al., 2013;
Hao et al., 2014; Kalladka and Muir, 2014). Conversely, overexpression
of neuroprotective factors such as Bcl-2, adenosine, and myocyte en-
hancer factor 2C in ES-cell derived cells have also been shown to be
protective in stroke models (Ishikawa et al., 2013).
Proteomic analysis has demonstrated that MSC-derived vesicles
contain and release growth factors such as VEGF-A, TGFβ1, and IL-8, all
of which contribute to pro-angiogenic activities (Hao et al., 2014;
Merino-Gonzalez et al., 2016). Furthermore, MSC-derived extracellular
vesicles stimulate proliferation and migration of endothelial and
Fig. 3. Organ specific effects of stem cells in IR injury.
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vascular smooth muscle cells via induction of transcription factors via
HGF activation of LIF and STAT-1 that are involved in pro-angiogenic
pathways (Merino-Gonzalez et al., 2016). It has been reported that
conditioned medium collected from MSCs is able to significantly in-
crease numbers of migrated endothelial cells (HUVEC) and increase
capillary tube lengths in matrigel matrix (Yang et al., 2018) (Merino-
Gonzalez et al., 2016). MSCs have been proven to be effective in sup-
pression of inflammation post-ischemic stroke through induction of
polyamine (e.g. putrescine) that promote actin filament reorganization
(Alexander et al., 1987) and could alter the integrity of BBB in brain
injury (Shin et al., 2016). Current studies have considered the ability of
placental-derived mesenchymal stem cells to modulate the micro-
environment in a way that promotes endogenous neurogenesis through
increased vascular density, increased expression of vascular endothelial
growth factors, and basic fibroblast growth factor (Ishikawa et al.,
2013).
Animal studies of stem cells in ischemic stroke
Administration of MSCs can reduce infarct volumes and improve
functional outcomes in models of stroke (Broughton et al., 2012). There
are data showing that embryonic stem cell-derived neural progenitor
cells transplanted into stroke mice contribute to the repair of damaged
tissue. Similarly endothelial cell derived from ES cells potentially pro-
mote vascular regeneration and reduction of infarct volume in stroke
mice models (Ishikawa et al., 2013). Moreover, intravenous delivery of
NSCs reduces numbers of pro-injurious OX-42+ microglia, attenuates
neutrophil infiltration and myeloperoxidase signal in brain lesions, and
downregulates the expression of several inflammatory mediators in-
cluding TNF-α, IL-1b, IL-6, as well as leptin receptors (Hao et al., 2014).
Implantation of umbilical cord mesenchymal stem cells (UCMSCs) into
ischemia-damaged areas of the brain in rats post-stroke induced bene-
ficial angiogenesis and stabilization of the vasculature mediated by the
angiopoietin (Ang)/Tie system (Zhao et al., 2015).
Intravenous administration of hPD-MSCs suppress both endogenous
lymphocyte reaction due to expression of HLA-G, and mitogen-induced
and allogeneic lymphocyte proliferation in CD4+ and CD8+ T cell
populations (Chen et al., 2013). Double infusion of placenta derived
MSCs (10^6 cells) at 8 and 24 hours post-stroke improved functional
outcomes; this was not achieved by a single injection of cells at 24h
(Kranz et al., 2010; Shehadah et al., 2014). Administration of PDA001
positively influenced endothelial proliferation, vascular densities and
perimeter into the ischemic brains of both young and older rats. Im-
provements in functional outcome recoveries with PDA001 adminis-
tration 24 h after MCAo likely reflect neurorestorative rather than a
neuroprotective effect (Shehadah et al., 2014). In both young and older
rats, treatment with 10,000 PDA001 cells, significantly increased
numbers of BrdU immunoreactive endothelial cells which indicates
active angiogenesis. Injection of 4 million PDA001 cells 4h after MCAo
significantly decreased TUNEL and cleaved caspase 3 abundance in the
post-ischemic brain, however, it increased the expression levels of
VEGF-A and HGF in the IBZ. In contrast to the idea that implanted stem
cells are expected to migrate and replace the injured tissue, only a few
of these PDA001 cells successfully migrated into the ischemic tissue
(Chen et al., 2013). Increased levels of neuroblast production following
ischemic stroke has been reported in the subventricular zone in both
rats and human brain biopsy after stroke (Kalladka and Muir, 2014).
Cerebral endothelial cells have been shown to suppress proliferation
of neural stem cells via interactions involving endothelial ephrinB2 and
Jagged1 with neural stem cell Notch and Eph. Integrins alpha-6 and
beta-1 released from cerebral vasculature are also critical in regulation
of biologic function of neural stem and progenitor cells (Zhang et al.,
2016).
2.2. Stem cells in myocardial infarction
Acute myocardial infarction (AMI) represents the most common and
devastating cardiovascular event worldwide, leading to ischemic heart
damage by inducing apoptosis, necrosis, inflammatory responses, and
remodeling (Madigan and Atoui, 2018). Ischemic heart damage triggers
scar formation, ventricular stiffness, and unfavorably altered myo-
cardial contractility (Cambria et al., 2017; Madigan and Atoui, 2018).
Most recently, stem cell therapy has shown to be a promising
therapeutic approach for improving AMI outcomes (Carvalho et al.,
2015) (Garbern and Lee, 2013) (Cambria et al., 2017; Madigan and
Atoui, 2018). A meta-analysis on stem cell therapy suggests that SCT
leads to significant decreases in mortality and rehospitalization, im-
proved left ventricular ejection fraction (LVEF), and improved exercise
capacity, and quality of life (Cambria et al., 2017). Several cell types
including skeletal myoblasts (SMs), bone marrow mononuclear cells
(BMMNCs), hematopoietic stem cells (HSCs), endothelial progenitor
cells (EPCs), and mesenchymal stem cells have been used for heart
repair and regeneration (Katarzyna, 2017) (Schaun et al., 2016)
(Cambria et al., 2017).
Mechanistically, MSC administration improved left ventricle ejec-
tion function post-MI through several mechanisms including differ-
entiation into vascular endothelial and cardiomyocytes, recruitment of
endogenous stem cells and paracrine signaling, although the differ-
entiation of MSCs into cardiomyocytes remains highly disputed and
controversial (Cambria et al., 2017; Madigan and Atoui, 2018).
Paracrine actions of MSCs activate homing of endogenous stem
cells, and promote secretion of immunomodulatory and trophic factors
that promote vascularization (Burchfield and Dimmeler, 2008) (Wang
et al., 2012) (Cambria et al., 2017) (Madigan and Atoui, 2018). Ad-
ministration of MSCs showed beneficial effects on mechanical, re-
generative, and clinical outcomes in cardiac infarct model (Jeong et al.,
2018). Comparing the effects of MSCs and bone marrow derived stem
cells (BM-MSCs) in chronic ischemic heart disease showed that MSCs
were more effective in improving heart function. Potential mechanisms
which might have contributed to biological efficacy of MSCs therapy
include: 1) differentiation of MSCs into cardiomyocytes or other
structural cell types, 2) development of new blood vessels networks
after MI, 3) secretion of paracrine mediators from MSCs, 4) stimulation
of endogenous cardiac precursors to repair the injured tissues (Jeong
et al., 2018). HSCs enhanced angiogenesis and vasculogenesis, poten-
tially due to their paracrine effects but not through myocardial differ-
entiation (Cambria et al., 2017).
Most recently, exosomes secreted from cardiomyocytes have shown
to be effective in cell survival, angiogenesis, immune responses, and
intercellular contacts (Hu et al., 2018). The secretome of stem cells
cumulatively includes soluble paracrine factors as well as microRNA-
enriched extracellular vesicles released by stem cells, which have de-
monstrated to be beneficial in regeneration of the injured myocardial
tissues (Bollini et al., 2018).
However, several studies still reported higher vascular densities,
increased cardiomyocyte survival and improvement of cardiac function
following administration of amniotic fluid stem cells where it has been
suggests that paracrine effects of stem cell-secreted factors promote
cell-cell interactions and maintain a regenerative microenvironment for
injured cardiac tissues (Danieli et al., 2015) (Bollini et al., 2018).
Therapeutic effects of placental stem cell on the injured cardiac
tissues could be related to their cardiomyocyte differentiation potential
or to the specific paracrine effects such as anti-apoptotic, pro-angio-
genic, and immunomodulatory properties (Liu et al., 2015b) (Li et al.,
2017b) (Bollini et al., 2018). Few studies provided evidence of differ-
entiation of placenta stem cells toward cardiovascular and cardiomyo-
cyte cells (Okamoto et al., 2007) (Bollini et al., 2018).
Animal studies of stem cells in MI
Bone marrow derived MSCs have become an attractive candidate for
cell therapy in myocardial infarction (MI) due to their multi-lineage
potential, high rate of proliferation, immune privileged status, and
more interestingly, their ability to implant and apparently differentiate
into cardiomyocytes and vascular cells in animal models of (Hu et al.,
2018; Jeong et al., 2018). Intravascular injection of adipose tissue
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mesenchymal stem cells (ATMSCs) for ischemic cardiomyopathy
showed improvements in LV mass and contractility via differentiation
of these cells into cardiomyocytes (Madigan and Atoui, 2018).
Hu et al., 2018 have reported that exosomes produced by cardio-
myocytes significantly increase the expression of apoptosis-related
proteins and apoptotic rate of BMSCs under oxidative stress conditions,
suggesting an accelerated transplanted BMSCs injury in infarcted heart
due to poor survival of transplanted cells (Hu et al., 2018).
Immature human amniotic-derived progenitors like amniotic fluid-
derived mesenchymal stem cells (AF-MSC) and human amniotic FACS
sorting stem cells (hAFSC), were seen to be more prone to acquire
cardiomyocyte-like phenotype upon in vitro stimulation with rodent
neonatal cardiomyocytes or chemical treatment with 5-aza-2’-deox-
ycytidine, TGF-β1, or by a mixture of hyaluronic, butyric and retinoic
acid (Bollini et al., 2018).
Despite the extensive ex-vivo reprogramming of amniotic stem cells,
there is a low rate of in vivo engraftment and differentiation of trans-
planted amniotic fluid stem cells in MI models. Lazzarini et al., 2016
demonstrated that paracrine cardio-protective potential of hAFSC
conditioned media was through activation of the PI3K/Akt signaling
pathway, decreased DNA damage, nuclear transportation of NF-kB, and
upregulation of the NF-κB-regulated genes such as IL-6 and CXCL1
which maintain cardiomyocyte survival (Lazzarini et al., 2016).
Placenta-derived stem cells have been shown to be cardioprotective
by inhibition of cardiomyocyte apoptosis both in vivo and in vitro (Zhao
et al., 2016). Pro-angiogenic and proliferative potentials of different
types of placenta-derived stem cells in infarcted myocardium are
mainly mediated by exosomes and vesicles produced by the cells (Liu
et al., 2015a; Zhao et al., 2016).
2.3. Stem cells in renal I/RI
In addition to stroke and ischemic heart disease, several studies
have shown beneficial effects of stem cells in renal I/RI which is mainly
characterized by tubular apoptosis and necrosis, glomerular injury and
inflammation (Semedo et al., 2007). In addition to acute renal failure,
renal I/R injury can lead to loss and/or delayed recovery of trans-
planted kidney functions (Si et al., 2015). Renal I/RI also lead to de-
struction of renal corpuscles, loss of almost all glomerular tufts, peri-
tubular congestion, and cytoplasmic vacuolation, pycnotic nuclei and
acidophilic hyaline casts in tubules. These effects were also reversed by
an injection of stem cells at 72 hours (Yuan et al., 2017a).
As in other settings, combinations of stem cell homing, differ-
entiation and secretion of paracrine effects of stem cells are thought to
be important in suppression of renal I/R. It has been proposed that the
extracellular vesicle (EVs) released from human-induced pluripotent
stem cell–derived mesenchymal stromal cells (hiPSC-MSCs) can
dampen necroptosis, a programmed form of necrosis, in renal I/RI by
delivering specificity protein 1 (SP1), a transcriptional activator of SK1
into renal cells, thereby activating SK1 expression and SP1 formation, a
potent ligand for cell growth and survival (Yuan et al., 2017a). Com-
bined treatment with MSCs and stem cell derived-EVs had an additive
beneficial effect on kidney restitution (Aghajani Nargesi et al., 2017;
Chen et al., 2017; Gu et al., 2016; Zou et al., 2016). Several other in
vitro and in vivo studies on mesenchymal stem cell derived EVs showed
that these EVs can decrease cell damage and death, restore prolifera-
tion, reduce oxidative stress and expression of nuclear factor E2-related
factor-2 involved in regulation of cellular oxidative stress, increase the
expression of NADPH oxidase-2, decrease the number of injurious
macrophages, decrease the number of natural killer cells, decrease the
expression of pro-inflammatory cytokines, including TNF-α, IL-1β and
chemokine C-X-C motif ligand-1 (CXCL1) after renal I/RI. These bene-
ficial effects of EVs have been linked to either direct transfer of mRNAs
and factors such as VEGF-A involved in these processes or down-
regulation of microRNAs involved in apoptosis, hypoxia, mitochondrial
fission and cytoskeletal reorganization (Aghajani Nargesi et al., 2017;
Chen et al., 2017; Gu et al., 2016; Zou et al., 2016). MSCs secrete mi-
croRNA-233 directly to release onto renal tubular epithelial cells in-
crease total cell viability and levels of several growth factors including
hepatocyte growth factor (HGF), insulin-like growth factor-1 (IGF-1),
transforming growth factor beta (TGF-β), and vascular endothelial
growth factor (VEGF) mainly by inhibiting NLR family-pyrin domain
containing 3 (NLRP3) signaling which has been shown to play role in
cytokine production and renal injuries (Yuan et al., 2017b). Lin et al.,
2003 demonstrated that hematopoietic stem cells can differentiate into
renal tubular cells and reduce renal I/RI (Lin et al., 2003). Stem cell
factor (SCF) and granulocyte colony-stimulating factor (G-CSF) have
been shown to mobilize the bone marrow stem cells (BMSCs) to site of
tubular injury and thus repair injury from acute tubular necrosis (Bi
et al., 2015).
Animal studies of SC in renal I/R
Rat models have shown that CD73, CD105 and CD90 positive MSC
led to better renal outcomes after renal I/RI as shown by reduced
plasma levels of creatinine and urea, increased kidney tissue levels of
IL-4 (an anti-inflammatory cytokine) and reduced level of IL-1 β (a pro-
inflammatory cytokine). Additionally, MSC-treated kidney tissues had
more nuclei reactive for Proliferating Cell Nuclear antigen (PCNA), an
essential factor for DNA polymerase activity and replication, support
more early tubular regeneration compared to non-treated controls
(Sadek et al., 2013; Semedo et al., 2007). Tang et al., 2018 showed that
human bone marrow MSC (hBM-MSCs) led to the reduction in macro-
phage infiltration, serum levels of C5a and expression of C5aR and TNF-
α & IL-1β, pro-inflammatory cytokines, in renal tissues in mice (Tang
et al., 2018). The treatment of LPS-activated macrophages with hBM-
MSCs in vitro led to decline in expression of C5aR, secretion of pro-
inflammatory factors TNF-α, IL-6, and nitric oxide and activation of NF-
κB signaling (Sadek et al., 2013). Sadek et al., 2013 also showed that
induction of renal I/RI in rats led to partial or complete loss of the brush
borders and basement membrane in tubules. These effects were re-
versed by injection of MSC after 72 hours, but not injection of cells at 24
hours (Sadek et al., 2013). Adipose tissue–derived mesenchymal stem
cells (ADMSCs) also suppressed renal fibrosis and promotes tubular
regeneration primarily by releasing exosomes which upregulate the
expression of Sox 9, a transcription factor involved in kidney devel-
opment (Zhu et al., 2017). Additionally, ADMSCs decreased renal
apoptosis, injury score, proteinuria, serum creatinine and expression of
proteins associated with inflammation in particular HGF and SDF1, IL-
6, TNF-α, IL-1β, IFN-γ, TNF-α, IFN-γ, TGF-β and increased the expres-
sion of, IL-10 (an anti-inflammatory cytokine) and Bcl-2 (an anti-
apoptotic factor) (Sheashaa et al., 2016; Zhang et al., 2017). Ischemic
preconditioning has been shown to increase the potential of ADMSCs as
evident by further increase in expression of HIF-1α, SDF-1α, CD31, and
Ki67 and further decrease in expression of caspase-3 and CD45 com-
pared to individual treatments (stem cells and ischemic preconditioning
alone) (Hussein et al., 2016). Tian et al., 2017 demonstrated (in rats)
that treatment with human urine-derived stem cells decreased serum
creatinine, blood urea nitrogen levels, tubular injury scores, numbers of
apoptotic cells and expression of INF-γ & IL-1β while increasing num-
bers of proliferating cells and mRNA expression levels of anti-in-
flammatory cytokines, in particular IL-10 and TGF-β1 (Tian et al.,
2017).
Fahmy et al., 2017 concluded that human cord mesenchymal stem
cell can reduce serum levels of creatinine, urea, uric acid and oxidative
stress by increasing the levels of glutathione (GSH), catalase (CAT) and
glutathione-S-transferase (GST) (Fahmy et al., 2017). Human and
mouse-induced pluripotent stem cells attenuated the necrosis and
apoptosis in renal tissues and suppressed blood urea and serum crea-
tinine level after renal I/R while enhancing renal tubule recovery, cell
proliferation, and the expression of anti-inflammatory factors in parti-
cular IL-10, FGF, and TGF-β and pro-renal tubular repair factors such as
EGF, HGF, and PDGF (Li et al., 2015; Toyohara et al., 2015).
Conditioned culture medium derived from iPSC also attenuated
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renal I/RI in rats by reducing ROS generation, suppressing p38-MAPK
activation and decreasing the expression of TNF-α and NF-κB signaling
(Tarng et al., 2016). Stem cell antigen-1, a common stem cell marker,
has been shown to constitutively bind to TGFβ receptors I and II and
lead to silencing of TGFβ receptor-mediated Smad signaling which is
involved in formation of pro-inflammatory factors to improve renal
function after ischemia acute kidney injury (Camarata et al., 2015). Qiu
et al., 2014 demonstrated that umbilical cord mesenchymal stem cells
decreased the expression of ICAM-1 and suppressed neutrophil in-
filtration into renal tissues after renal I/RI in rats (Qiu et al., 2014).
After homing to injured kidneys, human mesenchymal stem cells
attenuated I/RI at least in part by changing macrophage polarization
toward the anti-inflammatory phenotype “M2” and by increasing ma-
trix metalloproteinase-9 activity (which acted to reduce levels of col-
lagen α1(I) and IV) (Wise et al., 2014).
Bone marrow stem cells (when injected either prior to ischemia or
with reperfusion) reversed the negative effects of I/R on renal mi-
tochondrial respiration by preserving normal levels of electron fluxes,
the electrochemical gradient for protons, ATP synthesis and mi-
tochondrial ROS generation (Beiral et al., 2014). The intravenous in-
jection of mesenchymal stem cells decreased tissue levels of mal-
ondialdehyde (MDA), whereas superoxide dismutase (SOD) and
glutathione peroxidase (GSH-Px) were increased upon the induction of
renal I/RI (Zhuo et al., 2011).
2.4. Stem cells in intestinal I/RI
Intestinal I/R injury is associated with high morbidity and mor-
tality, and frequently occurs during small bowel transplantation, ab-
dominal aortic aneurysm surgery, cardiopulmonary bypass, strangu-
lated hernias and hemorrhagic shock (Jiang et al., 2013). Intestinal I/R
has devastating effects on mucosal permeability, villus structure, mi-
tochondrial activity and can lead to translocation of pathogenic mi-
crobes into the circulation where they trigger systemic inflammation
(Grootjans et al., 2010; Guan et al., 2009). Animal studies have suc-
cessfully demonstrated the beneficial effects of the stem cells in at-
tenuation intestinal I/RI.
Mechanistically, less is known about the mechanism underlying the
beneficial effects of stem cells in intestinal I/RI. A study done on C57Bl/
6 mice showed that homing of MSCs to injured gut is very limited;
despite poor migration, MSCs were still able to exert anti-inflammatory
effects and improve tissue perfusion of the jejunum and ileum
(Kavanagh et al., 2015).
Animal Studies of SC in intestinal I/R
Mesenchymal stem cells (MSCs) increase superoxide dismutase
(SOD), catalase (CAT), and glutathione peroxidase (Gpx) activities, but
decrease malondialdehyde (MDA) in the intestine following ischemic
injury. MSCs also increased anti-inflammatory cytokines EP3 and IL-1ra
while decreasing pro-inflammatory cytokines e.g. IL1β, TGFβ-1, TNF-α,
IL-6, MIP2, and MPO (Inan et al., 2017). Additionally, MSCs have been
shown to have a synergetic effect on intestinal I/RI in combination with
electro-acupuncture and heparin-binding EGF-like growth factor,
measured as improved intestinal histology and solute permeability,
increased crypt cell proliferation and mucosal concentration of mRNA
for SDF-1, CXCR4, EGF, EGFR as well as lower mucosal NF-κBp65 and
serum pro-inflammatory cytokines (TNF-α, IL-6) levels (Geng et al.,
2016; Watkins et al., 2013).
Liu et al., 2014 showed that the hepatocyte growth factor c-Met
signaling pathway (HGF/c-Met) fulfills an important role in MSC mi-
gration towards the liver injured by intestinal ischemia-reperfusion,
and that subsequent repair of the liver can be induced by MSCs (Liu
et al., 2014). MSCs transplantation has been successful in decreasing
the TNF-α content of the bowel mucosa and intestinal mucosal NF-κB
expression. Furthermore, MSCs treatment increased expression of
pERK1/2 in the intestinal mucosa and PCNA in bowel mucosa (Jiang
et al., 2013). Bone marrow mesenchymal stem cells attenuated
intestinal injury due to I/R by reducing intestinal permeability and villi
injuries, ZO-1 downregulation, and tight junction disruption, thereby
maintaining intestinal mucosal barrier, probably by regulating the le-
vels of TNF-α (Jiang et al., 2011; Shen et al., 2013). The injection of
MSCs at the beginning of reperfusion in the superior mesenteric artery
occlusion model decrease injury to the intestinal barrier, suppressed
bacterial translocation, and was able to lower levels of serum lactate
(Abarbanell, 2010).
2.5. Stem cells in Hepatic I/RI
Liver I/RI is a major cause of diminished liver functioning following
liver surgery and commonly occurs during liver resection or trans-
plantation. Several factors contribute to hepatic I/R injury including
disturbed mitochondria respiration and oxidative stress (Tartaro et al.,
2018), intracellular calcium overload (Vasques et al., 2016), Kupffer
cell activation (Cheng et al., 2019) neutrophil infiltration (Hamada
et al., 2008) as well as cytokine and chemokine release (Cheng et al.,
2019) (Hamada et al., 2008) (Guan et al., 2014; Vasques et al., 2016).
While stem cells administered therapeutically often accumulate in
the spleen and liver, they can be further ‘encouraged’ to reach this
compartment. For example, intraportally injected BM-MSCs were found
to migrate into spleen and liver, rather than the brain, kidney, or lung
tissues in a rat liver I/R model (Nowacki et al., 2015).
Another study showed the equal distribution of MSCs to ischemic
and non-ischemic parts of the liver after systemic injection of labelled
MSCs (Isbambetov et al., 2016). However, when Saat et al., 2016 in-
travenously infused MSCs 2 hours before, or 1 hour after partial hepatic
ischemia/partial hepatectomy, many cells were trapped in the lungs
instead of migrating to the damaged liver (Saat et al., 2016).
The exosomes derived from human-induced pluripotent stem cell-
derived mesenchymal stromal cells (hiPSC-MSCs) protected against
liver ischemia-reperfusion, revealed as a decrease in hepatocyte ne-
crosis, sinusoidal congestion and serum levels of aspartate amino-
transferase (AST) and alanine aminotransferase (ALT) (Du et al., 2017;
Haga et al., 2017; Nong et al., 2016). This exosome treatment also in-
creased expression of proliferating cell nuclear antigen (PCNA) and
phosphohistone-H3. The authors concluded that exosome protection
involves direct fusion of exosomes with injured hepatocytes with in-
creased rate of sphingosine kinase and formation of sphinhosine-
1–phosphate (Du et al., 2017). Exosomes also decreased expression of
TNF-α, IL-6 and HMGB1 and the apoptotic markers (caspase-3; Bax)
with increased expression of antioxidants; GSH, GSH-Px and SOD (Haga
et al., 2017; Nong et al., 2016).
Animal Studies of stem cells in hepatic I/R
Wang et al., 2018 showed that bone marrow mesenchymal stem
cells suppressed liver ischemia–reperfusion injury by promoting ex-
pression of heme-oxygenase-1 (HO-1) and thus promoting HO-1 medi-
ated autophagy (Wang et al., 2018). Mesenchymal stem cell therapy
improved the survival rate and decreased ischemia reperfusion injury
by up-regulating mRNA expression of HGF, Bcl-2, Bcl-XL, IL-6, IL-10,
IP-10, and CXCR2 and downregulating TNF-α. MSC therapy also in-
creased the expression of p-c-Jun, cyclin D1, PCNA and NF-κB (Wang
et al., 2014). Saidi et al., 2014 showed that human adipose derived
mesenchymal stem cells improved survival, numbers of regenerating
cells and decreased serum IL-6 and alanine aminotransferase release
(Kanazawa et al., 2011; Saidi et al., 2014). MSCs also attenuated liver I/
R by reducing apoptosis and liver enzyme levels and increasing N-
acetyltransferase-8 (NAT8) (Fu et al., 2014). Pan et al., 2012 concluded
that MSCs confer protection by inactivating the MEK/ERK pathway
(Pan et al., 2012). Human adipose derived stem cells and elements of
their secretome decreased serum levels of IL-6, lowered neutrophil
transmigration and decreased ICAM-1 and PECAM-1 expression, all of
which improved histologic scores in a mouse hepatic I/R model (Lee
et al., 2015).
Rats transplanted with BM-MSCs via the portal vein show partial
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attenuation of liver I/RI with lower serum ALT and AST levels, lower
malondialdehyde (MDA) levels and maintaining superoxide dismutase
(SOD) and glutathione peroxidase (GSH-Px) activities. These stem cell
treated rats also had fewer apoptotic hepatocytes and lower levels of
BAX and caspase-3 (Jin et al., 2013).
2.6. Stem cells in retinal I/RI
Diabetic retinopathy, glaucoma and age-related macular degenera-
tion remain the most common causes of irreversible blindness in wes-
tern countries where retinal ischemia, cell death and inflammation are
central events in vision loss. Current treatments such as intraocular
injection of anti-VEGF and surgery can arrest the progression of disease
but do not affect the damaged retina (Mathew et al., 2019). Therefore,
there is a pressing need of a new and safer treatment. In this setting,
stem cells have proven benefits in retinal I/R injury which are mediated
both by stem cell-derived extracellular vesicles (EVs) and stem cell
differentiation.
An in vitro model using an oxygen-glucose deprivation (OGD) of
retinal ischemia showed that cell death was reduced, and cell pro-
liferation improved following treatment with MSC-derived EVs. The
endocytosis of EVs occurred in caveolar dependent fashion and medi-
ated by heparin sulfate proteoglycans (Mathew et al., 2019). The au-
thors also showed the beneficial effects of MSC-EVs in vivo. when EVs
were injected into the vitreous humor 24hr following retinal ischemia
inflammation and apoptosis decreased and functional recovery was
improved (Mathew et al., 2019). Bone marrow stem cell antigen 1
positive (Sca-1+) cells have been shown to home more selectively to the
retina and to differentiate more often into glial and microglial cells as
compared with Sca-1-cells (at 7 days following retinal I/R injury) (Shao
et al., 2018). Vascular progenitors from human embryonic stem cells
and cord blood-iPSCs were seen to home to and engraft into damaged
capillaries within the retina after 45 days in retinas of non-obese dia-
betic-SCID mice model exposed to I/R, when injected either systemi-
cally or into the vitreous (Park et al., 2014). Under I/R conditions, adult
rat hippocampus-derived neural stem cells have the potential to migrate
to the retinal inner layer within 2 weeks of transplantation. Adult rat
hippocampus-derived neural stem cells integrated into the retina and
expressed Map2ab, a mature neuron marker, 4 weeks following trans-
plantation (Kurimoto et al., 2001).
Animal studies of stem cells in retinal I/R
The overexpression of heme oxygenase-1 (HO-1) in MSCs using
lentivirus significantly decreased hydrogen peroxide-induced retinal
injury in vitro. HO-1 overexpression reduced ROS levels and apoptosis
and induced the activation of anti-apoptotic proteins like Akt and Bcl-2.
HO-1 also blocked the activation of pro-apoptotic proteins e.g. cleaved
caspase 3 and Bax. MSC-HO-1 treatment also reduced apoptosis and
oxidative stress, and prevented retinal thinning and enhanced SOD and
CAT activity in a rat retinal I/R model (Li et al., 2017a).
Lineage-negative stem cells transplanted 24 hours after pter-
ygopalatine artery ligation induced retinal I/R injury in mice, were seen
to migrate to the retina, where they decreased expression of GFAP, a
marker of astrocyte injury and increased expression of two neuro-
trophic factors BDNF and FGF2, (Minhas et al., 2017). Human bone
marrow-derived mesenchymal stem cells (BMSCs) preserved the in-
tegrity of the retina in a rat I/R model, where intravitreally BMSC-
treated retinas were shown to maintain significantly greater thickness 7
days after injury (Wang et al., 2017). The transplantation of retinal
progenitor cells into the subretinal space and superior colliculus also
improved electroretinography and visual evoked potentials in a rat
retinal I/R model (Li et al., 2014).
The subretinal injection of non-c-Myc iPSC significantly improved
electroretinography in the rat retinal I/R model, where stress was in-
duced by elevating intraocular pressure to 110 mmHg for one hour. The
non-c-Myc iPSC also improved retinal ganglion cell survival, increased
the activity of SOD and CAT, and decreased cellular ROS levels (Fang
et al., 2013). The transplantation of bone marrow derived mesenchymal
stem cells in the vitreous cavity attenuated the reduction in retinal
ganglion cell upon retinal I/R injury in rats. Most of the transplanted
cell migrated to the inner limiting membrane where several cells ex-
pressed neuron-neuron specific enolase (NSE), neurofilament (NF) and
neurotrophic factors including bFGF, BDNF and CNTF. However, in
control mice, stem cells were restricted to the vitreous cavity (Li et al.,
2009). The intravitreally transplanted adult rat hippocampal progenitor
cells (AHPCs) in the elevated intraocular pressure model differentiated
under both sets of conditions in normal and injured eyes. However, the
morphological integration of AHPCs into the inner retinal layer oc-
curred only in the ischemic eyes. Under normal conditions, stem cells
were confined to the vitreous inner limiting membrane. Additionally,
no functional benefits (assessed by pupil light reflexes and electro-
retinograms) were observed with AHPCs (Grozdanic et al., 2006).
Summary
The increasing use and acceptance of stem cells in forms of re-
generative medicine beyond bone marrow transplants suggest the ap-
propriate application of different types of stem cells in the prophylaxis
and treatment of acute and chronic forms of tissue injury resulting from
ischemia reperfusion. Among the forms of ischemia reperfusion injury,
stem cells have been intensively explored particularly in the settings of
ischemic stroke and myocardial infarction where they may both resti-
tute and restore functional and structural components of the heart and
brain which have been transiently or permanently injured by ischemic
stress. The benefits of stem cell use in other organ systems (kidney,
liver) have been successfully demonstrated much more widespread
application of stem cells in the treatment of reperfusion in general.
When administered chronically after ischemic episodes, (i.e. after
damage has been sustained by target organs), the ability of stem cells to
trans-differentiate into endothelial cells, neurons and glial support cell
lineages which may restitute cardiac and brain tissue and promote re-
vascularization, processes which are vital to restoring organ mass and
perfusion. However, it also appears true that stem cells acutely release
trophic factors (growth factors, exosomes) at and beyond the period of
reperfusion which preserves cardiomyocyte, neuronal and stromal
components in ischemia-stressed tissues. These processes may limit or
prevent initial reperfusion-induced events e.g. apoptosis which drive
extensive long-term tissue injury and fibrosis in I/RI. Therefore, stem
cells may improve clinical outcomes in I/RI through several different
but complementary mechanisms.
Stem cells may therefore represent the ideal ‘poly-pill’ therapy
which could positively influence medical outcomes at several different
phases after ischemic stress and through different pathway. Although
circulating and bone marrow derived stem cells as well as tissue-re-
sident stem cells share many characteristics which ‘cloak’ them from the
immune system, these different populations of stem cells might be used
to confer different types of protection reflecting their anatomic origins,
fate potential and the complement of factors they may be able to re-
lease.
Additionally, the targeting of stem cell therapeutics, especially in
the settings of stroke (via intra-thecal, intravenous or intraventricular in-
jection) and in myocardial infarction by intravenous delivery (or even
intramuscular injection) might achieve greater and more specific spa-
tial delivery of stem cells to these stressed regions. Future studies which
more fully characterize the subtle differences which distinguish dif-
ferent stem cell types may help identify and optimize treatments for
ischemic stress and injury and improve outcomes in these devastating
forms of tissue destruction.
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